← board
LEXX
Lexaria Bioscience Corp.distress 7/10 · high distress / dilution risk$0.55-1%today-64% from 52w high
Metabolic / Obesity 1
Lead: hypertension · target GLP-1 · est. market ~$25B (approx, global)
Revenue
pre-revenue
Liquidity
$4M
Runway
0.4 yrs
Shares 1y
+12%
Price & events
-32.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.4%
1D
-1.4%
1W
-3.0%
1M
-41.6%
3M
-35.2%
6M
-46.5%
1Y
-81.8%
2Y
-91.9%
5Y
-87.7%
All
Overview
- Market Cap
- $13.66M
- Volume
- 859
- 52 Week Range
- $0.53 – $1.53
- Total Shares
- 24.79M
- Float Shares
- 24.04M
- Short %
- 1.44%
- % Held by Insiders
- 3.32%
- % Held by Institutions
- 6.01%
- RVOL
- 0.01x
- Beta
- 0.34
Pipeline stages · 1 programs
Arm 1 - DehydraTECH-CBD alone, Arm 2 - DehydraTECH-semaglutide alone, Arm 3 - DehydraTECH-GLP-1
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-07-31 | Phase 1 | Arm 1 - DehydraTECH-CBD alone, Arm 2 - DehydraTECH-semaglutide alone, Arm 3 - DehydraTECH- | Type2diabetes | 148 | completed |
Catalyst news & presentations · 3
- 2025trial initiationsecondaryPhase 1Lexaria's proprietary delivery technology · Phase 1b hypertension study likely to begin in 2025 subject to financing.SEC 8-K
- within 15 days of September 26, 2025regulatory submissionFiled (NDA/BLA)File registration statement for resale of warrant sharesSEC 8-K
- mid-OctoberreadoutDehydraTECH · Cohort 2 dosing completion in animal study WEIGHT-A24-1SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $4 (+535% upside) · 2 analysts
- 2025-12-26HC Wainwright & Co.Buy
- 2025-07-29HC Wainwright & Co.Buy
- 2025-07-01HC Wainwright & Co.Buy
- 2025-01-24HC Wainwright & Co.Buy
- 2024-12-02HC Wainwright & Co.Buy
- 2024-11-25HC Wainwright & Co.Buy
Competitors — GLP-1
Recent news
- 2026-07-20Price to book forward of Lexaria Bioscience Corp. – NASDAQ:LEXX - TradingView
- 2026-07-13Lexaria Bioscience narrows Q3 loss to $(0.08) per share - scanx.trade
- 2026-07-13Lexaria Bioscience Corp. 2026: Revenue $0 EPS ($0.08) — 10-Q Summary - TradingView
- 2026-07-13Lexaria Bioscience (NASDAQ: LEXX) narrows loss but warns on cash and Nasdaq bid - Stock Titan
- 2026-07-06Lexaria pitches DehydraTECH to drugmakers at BIO as GLP-1 safety focus grows - Stock Titan
- 2026-07-06Lexaria Updates Business Development - Investing News Network
- 2026-07-06Lexaria reports pharmaceutical partnership discussions at BIO - Investing.com
- 2026-06-25Lexaria's Human Study GLP-1-H26-7 Has Begun Dosing on Schedule - Investing News Network
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.